GSK to layoff R&D staff in UK, US due to rethink on its drug development ops

By PharmaCompass

2019-04-25

Impressions: 75 Article

British drug major GlaxoSmithKline’s new R&D chief Hal Barron has made clear his interest in refocusing the group R&D. And this focus is beginning to play out with impending layoffs in GSK’s big R&D center in Stevenage (UK) and its second big R&D hub near Philadelphia (US).

In a statement issued last week, GSK said a “small number” of roles would be affected by the layoffs in Stevenage. “We have identified where changes are necessary to ensure we can fully support our evolving pipeline priorities. We anticipate a small number of roles will be directly impacted by these changes but continue to expect GSK’s R&D operations to grow overall with increased investment.”

However, an Endpoints News story said GSK will extend the layoffs to Upper Providence in Pennsylvania. According to the article, Barron is axing some 240 to 250 staffers in Upper Providence and Stevenage. “That includes a heavy concentration on chemists, including a few senior chemists in the group. Some administrative staffers are also getting hit,” the report said.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass